Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Array Celebrates BEACON Of Hope For Anti-BRAF/MEK/EGFR Triplet In Colorectal Cancer

Executive Summary

New data on Array BioPharma's encorafenib and binimetinib together with cetuximab add hopes for its future in colorectal cancer. Recent strong data in melanoma for the BRAF/MEK combo are expected to be followed by its first US approval in the coming days.

You may also be interested in...

Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal

Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.

Pierre Fabre Set To Shake Up EU Melanoma Market

Having just got the nod for the combination of Braftovi and Mektovi, the French company believes the strength of its overall survival data will see the therapy successfully compete with other BRAF/MEK combos and immunotherapies for melanoma.

Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts